Karuna Therapeutics, Inc. announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia.
Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50
Discover how telehealth is revolutionizing veteran healthcare, providing high-quality care regardless of location with essential use cases like video consultations, remote monitoring and telestroke.
Transforming veteran healthcare: How telehealth is changing the game Read More »
OEMs need to rethink how to deliver scalable, flexible service, especially in economic uncertainty.
How OEMs can budget aftermarket service in a recession Read More »
XNK Therapeutics announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.
New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics’ investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.
Antengene Corporation Limited announced the publication of abstracts for five posters that will be presented during the upcoming 2023 American Association for Cancer Research Annual Meeting, taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States.
Oxford Nanopore Technologies plc and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, announce a collaboration to make available 4bases kits with Oxford Nanopore sequencing technology.
NS Pharma is pleased to announce participation in the Muscular Dystrophy Association’s Clinical & Scientific Congress 2023 being held in Dallas, Texas. The company will be presenting previously reported long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO®.
Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma®, an essential one-time gene therapy for the treatment of spinal muscular atrophy.
